TEACH completes recruitment for HIV patient study
The study concerns MGN1703, an immunotherapy for HIV. The goal is to determine whether MGN1703 is able to activate the inherent, adaptive immune system that is within HIV patients. This will help the immune system to kill the cells infected with HIV.
“We are pleased that the enrollment for TEACH has been completed and that treatment with MGN1703 is well tolerated,” Dr. Alfredo Zurlo, chief medical officer of MOLOGEN AG, said. “We look forward to seeing all the results next year.”
The scientists will conduct the trial within two different hospital centers located in Denmark. Funding has been donated from the American Foundation for AIDS Research (amfAR). MOLOGEN has supplied the researchers with MGN1703, as this will be the first time that the immunotherapy has been used in patients who have a disease that is not cancer.
MGN1703, which can be expanded into a variety of applications, is being investigated in a trial called IMPALA, which studies colorectal cancer. MGN1703 is also being studied in IMPULSE, a randomized trial about small cell lung cancer.
The researchers expect to announce the results of the study by the second quarter of 2016.